...
首页> 外文期刊>Journal of children's orthopaedics >Induction of periosteal bone formation by intraosseous BMP-2 injection in a mouse model of osteogenesis imperfecta
【24h】

Induction of periosteal bone formation by intraosseous BMP-2 injection in a mouse model of osteogenesis imperfecta

机译:骨内注射BMP-2在成骨不全症小鼠模型中诱导骨膜骨形成

获取原文

摘要

Purpose Surgical interventions are routinely performed on children with osteogenesis imperfecta (OI) to stabilize long bones, often post fracture. We speculated that a combination of intramedullary reaming and intraosseous injection of recombinant bone morphogenetic protein-2 (BMP-2) could enhance periosteal ossification and ultimately cortical thickness and strength. This approach was conceptually tested in a preclinical model of genetic bone fragility. Methods Six experimental groups were tested including no treatment, intramedullary reaming, and reaming with 5 μg BMP-2 injection performed in the tibiae of both wild type (WT) and Col1a2 ~( G610C/+ ) (OI, Amish mutation) mice. Bone formation was examined at a two-week time point in ex vivo specimens by micro-computed tomography (microCT) analysis and histomorphometry with a dynamic bone label. Results MicroCT data illustrated increases in tibial cortical thickness with intramedullary reaming alone (Saline) and reaming plus BMP-2 injection (BMP-2) compared to no intervention controls. In the OI mice, the periosteal bone increase was not statistically significant with Saline but there was an increase of +192% (p = 0.053) with BMP-2 injection. Dynamic histomorphometry on calcein label was used to quantify new woven bone formation; while BMP-2 induced greater bone formation than Saline, the anabolic response was blunted overall in the OI groups. Conclusions These data indicate that targeting the intramedullary compartment via reaming and intraosseous BMP-2 delivery can lead to gains in cortical bone parameters. It is suggested that the next step is to validate safety and functional improvements in a clinical OI setting.
机译:目的经常对成骨不全症(OI)患儿进行手术干预,以稳定长骨,经常在骨折后进行。我们推测髓内扩孔和骨内注射重组骨形态发生蛋白2(BMP-2)的组合可以增强骨膜骨化,并最终增强皮质的厚度和强度。在遗传性骨脆性的临床前模型中对该方法进行了概念测试。方法对六个实验组进行了试验,包括不治疗,髓内扩孔和在野生型(WT)和Col1a2〜(G610C / +)(OI,Amish突变)小鼠胫骨中进行5μgBMP-2注射扩孔。在两周的时间点,通过微计算机断层扫描(microCT)分析和带有动态骨标记的组织形态测定法检查离体标本中的骨形成。结果MicroCT数据显示,与无干预对照组相比,仅进行髓内扩孔(盐水)和扩孔加BMP-2注射(BMP-2)时,胫骨皮质厚度增加。在OI小鼠中,盐水对骨膜骨的增加没有统计学意义,但是BMP-2注射增加了+ 192%(p = 0.053)。钙黄绿素标记上的动态组织形态计量学用于量化新编织骨的形成;虽然BMP-2诱导的骨形成比盐水大,但OI组的合成代谢反应总体减弱。结论这些数据表明,通过扩孔和骨内BMP-2递送靶向髓内腔可导致皮质骨参数的增加。建议下一步是验证临床OI设置中的安全性和功能改进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号